Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.

European journal of clinical pharmacology - 1 Apr 2022

Long Jiangchuan, Liu Yongjian, Duan Yaqian, Li Yang, Yang Gangyi, Ren Ziyu, Tao Wei, Liu Dongfang

Abstract excerpt

PURPOSE: Gastrointestinal adverse reactions (GIARs) to liraglutide exhibit significant individual differences in type 2 diabetes. This study investigated the association between glucagon-like peptide-1 receptor (GLP-1R) single-nucleotide polymorphisms (SNPs) and GIARs. METHODS: Adverse events of liraglutide were observed in 376 T2DM patients. Seven tag SNPs at GLP-1R were sequenced in 152 participants. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Hypoglycemic Agents

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 35034150
DOI: 10.1007/s00228-021-03225-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.PMID 35034150Read ↗

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read ↗

Exploring the off-Label use of liraglutide in the treatment of obesity: a reviewSemantic proximity Read ↗

Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitusSemantic proximity Read ↗

Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read ↗

Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety OutcomesSemantic proximity Read ↗

Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity Read ↗

Exploration of suspected adverse drug reactions (Loose motion and Diarrhea) of Dapagliflozin during the treatment of type-2diabetes mellitus: A Case ReportSemantic proximity Read ↗

Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature reviewSemantic proximity Read ↗

Genetic predictors of GLP1 receptor agonist weight loss and side effects.Semantic proximity Read ↗

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity Read ↗

Clinical assessment of liraglutide use in prediabetic and obese schizophrenic patients: A systematic literature review and meta-analysisSemantic proximity Read ↗

Effect of liraglutide on expression of inflammatory genes in type 2 diabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.